Changes to Articles of Incorporation, Bylaws, or Fiscal Year

Seaport Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Seaport Therapeutics, Inc. on May 4, 2026. The filing reports corporate governance actions taken in connection with the consummation of the Company's initial public offering (IPO). The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "SPTX."

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on amendments to the Company's charter documents and does not contain financial performance data.

Material Changes

The Company filed an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws effective immediately prior to and upon the consummation of its IPO. Key changes include:

  • Capital Structure: Authorization of 700,000,000 shares of common stock, comprising 500,000,000 voting shares and 200,000,000 non-voting shares.
  • Preferred Stock: Elimination of all references to previously existing series of preferred stock and authorization of 10,000,000 shares of undesignated preferred stock.
  • Governance: Establishment of procedures for stockholder actions, advance notice for proposals and director nominations, and conformity with the new Certificate of Incorporation.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves solely to disclose the legal amendments to the Company's organizational documents.

Key Facts for Investor Verification

  • Verify the exact number of shares issued and outstanding following the IPO, as the filing only states the authorized share count.
  • Confirm the terms of the 10,000,000 authorized undesignated preferred shares, as specific rights and preferences are not detailed in this summary.
  • Review the full text of the Amended and Restated Bylaws (Exhibit 3.2) for specific details on director nomination procedures and stockholder meeting protocols.
  • Check subsequent filings for the Company's first post-IPO financial results, as this 8-K contains no financial data.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.